| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | $33.54B+3.6% | $32.36B+3.6% | $31.23B-1.4% | $31.69B+5.2% | $30.12B+4.2% | $28.91B-5.4% | $30.56B+304.9% | $7.55B+0.9% | $7.48B+1.3% | $7.38B |
| Cost of products sold, excluding amortization of intangible assets | $11.63B+3.7% | $11.22B+4.6% | $10.72B+5.7% | $10.14B-3.2% | $10.48B+11.2% | $9.42B+2.9% | $9.15B+1.0% | $9.07B-2.4% | $9.29B | — |
| Research and development expense | $2.73B-0.1% | $2.73B+1.4% | $2.70B-1.8% | $2.75B+10.1% | $2.49B+6.9% | $2.33B+0.0% | $2.33B+3.3% | $2.26B+2.9% | $2.19B | — |
| Selling, general, and administrative expense | $10.85B+1.1% | $10.74B+3.1% | $10.41B+1.2% | $10.29B+1.4% | $10.15B+0.4% | $10.11B-3.0% | $10.42B+1.8% | $10.24B+2.2% | $10.02B | — |
| Amortization of intangible assets | $1.81B+6.7% | $1.69B-0.3% | $1.70B-2.0% | $1.73B-2.8% | $1.78B+1.5% | $1.76B-0.5% | $1.76B-3.2% | $1.82B-7.9% | $1.98B | — |
| Restructuring charges, net | $267.0M+18.1% | $226.0M-39.7% | $375.0M+525.0% | $60.0M-79.5% | $293.0M+148.3% | $118.0M-40.4% | $198.0M+560.0% | $30.0M-90.1% | $303.0M | — |
| Certain litigation charges, net | $317.0M+112.8% | $149.0M+596.7% | -$30.0M-131.6% | $95.0M-19.5% | $118.0M | — | — | — | — | — |
| Other operating (income) expense, net | -$23.0M-105.0% | $464.0M+454.2% | -$131.0M-115.2% | $862.0M+173.7% | $315.0M+343.7% | $71.0M-72.5% | $258.0M-51.8% | $535.0M+123.8% | $239.0M | — |
| Operating profit | $5.96B+15.8% | $5.14B-6.2% | $5.49B-4.6% | $5.75B+28.3% | $4.48B-6.4% | $4.79B-23.6% | $6.27B-5.6% | $6.64B+23.4% | $5.38B | — |
| Other non-operating income, net | -$402.0M+2.4% | -$412.0M+20.0% | -$515.0M-61.9% | -$318.0M+5.4% | -$336.0M+5.6% | -$356.0M+4.6% | -$373.0M-106.1% | -$181.0M+42.2% | -$313.0M | — |
| Interest expense, net | $729.0M+1.4% | $719.0M+13.1% | $636.0M+15.0% | $553.0M-40.2% | $925.0M | — | — | — | — | — |
| Income before income taxes | $5.63B+16.4% | $4.84B-9.8% | $5.36B-2.8% | $5.52B+41.6% | $3.90B-3.9% | $4.05B-22.0% | $5.20B | — | — | — |
| Income tax provision | $936.0M-17.4% | $1.13B-28.3% | $1.58B+246.5% | $456.0M+72.1% | $265.0M+135.3% | -$751.0M-237.3% | $547.0M-78.8% | $2.58B+346.4% | $578.0M | — |
| Net income | $4.69B+26.6% | $3.71B-2.1% | $3.78B-25.2% | $5.06B+39.4% | $3.63B-24.5% | $4.81B+3.4% | $4.65B+265.9% | $1.27B+13.5% | $1.12B+4.0% | $1.08B |
| Net income attributable to noncontrolling interests | -$29.0M-3.6% | -$28.0M-7.7% | -$26.0M-18.2% | -$22.0M+8.3% | -$24.0M-41.2% | -$17.0M+10.5% | -$19.0M-311.1% | $9.0M+125.0% | $4.0M | — |
| Net income attributable to Medtronic | $4.66B+26.8% | $3.68B-2.2% | $3.76B-25.4% | $5.04B+39.7% | $3.61B-24.7% | $4.79B+3.4% | $4.63B+264.9% | $1.27B+13.8% | $1.11B+3.7% | $1.07B |
| Basic earnings per share (in dollars per share) | $3630000.00+31.0% | $2770000.00-2.1% | $2830000.00-24.5% | $3750000.00+39.9% | $2680000.00-24.9% | $3570000.00+3.8% | $3440000.00+262.1% | $950000.00+14.5% | $830000.00+5.1% | $790000.00 |
| Diluted earnings per share (in dollars per share) | $3610000.00+30.8% | $2760000.00-2.1% | $2820000.00-24.4% | $3730000.00+40.2% | $2660000.00-24.9% | $3540000.00+3.8% | $3410000.00+262.8% | $940000.00+14.6% | $820000.00+3.8% | $790000.00 |
| Basic weighted average shares outstanding (in shares) | 1.29B-3.2% | 1.33B-0.2% | 1.33B-0.9% | 1.34B-0.2% | 1.34B+0.3% | 1.34B-0.4% | 1.35B-0.8% | 1.36B-1.6% | 1.38B | — |
| Diluted weighted average shares outstanding (in shares) | 1.29B-3.0% | 1.33B-0.2% | 1.33B-1.4% | 1.35B-0.2% | 1.35B+0.2% | 1.35B-0.5% | 1.36B-0.8% | 1.37B-1.7% | 1.39B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.